KDR and neoplasm: In line with these data, we found that VEGFR inhibition with Vatalanib (PTK787), as well as KO of tumor VEGF-A via CRISPR-Cas9, resulted in increased formation of liver and rib cage metastasis with strong Vimentin expression in mice with SCLC (Supplemental Figure 13).